FDA accepts IND for Mustang Bio's MB-109 combo therapy for recurrent glioblastoma

MUSTANG BIO, INC.

IND accepted within 30 days of submission for MB-109 (MB-101 CAR-T + MB-108 oncolytic virus).
Phase 1 trial to start 2024; will test safety, tolerability, efficacy in recurrent GBM and high-grade astrocytoma.
Prior MB-101 alone saw complete responses lasting 7.5 and 31+ months in patients with hot tumors.
Study to enroll at City of Hope and University of Alabama at Birmingham.
Median overall survival for recurrent GBM is 6 months; combo aims to improve outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.